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ORIGINAL ARTICLE
Pneumonia is the eighth most common cause of
death in Taiwan.1 The mortality rate of community-
acquired pneumonia (CAP) is around 14–18%.2,3
Most of the patients are treated with empiric 
antibiotics, but 10–20% of CAP patients fail 
in their initial empiric treatment.3 Therefore, we
decided to search for reliable prognostic markers
that could rapidly identify those who would have
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Background/Purpose: To evaluate the roles of plasma sTREM-1 (soluble triggering receptor expressed on
myeloid cells-1) and C-reactive protein (CRP) in predicting treatment response in patients with community-
acquired pneumonia (CAP).
Methods: Patients with CAP were enrolled prospectively at a medical center in central Taiwan from
September 1, 2004 to July 31, 2005. They were treated according to the guidelines proposed by the American
Thoracic Society. Patients were noted as nonresponsive to initial treatment if they had one of the following:
persistent fever for more than 3 days, progression on chest radiograph, switching to other antibiotics, or
need of mechanical ventilation and/or chest tube drainage.
Results: Fifty-eight patients (43 males/15 females; mean age, 67 ± 21 years) with CAP were enrolled. Twelve
(12/58, 21%) were nonresponsive. In the response group, CRP was reduced up to 58% from day 1 to day
3 (from 18.8 to 7.8 mg/dL), whereas sTREM-1 was reduced by only 15% (from 32.8 to 28.1 pg/mL). In the
nonresponse group, CRP still declined 20% (from 22.2 to 17.7 mg/dL), whereas sTREM-1 was persistently
high (from 61.7 to 63.7 pg/mL). Using multivariate logistic regression analysis, both CRP (p = 0.006) and
sTREM-1 (p = 0.046) on day 3 predicted treatment response significantly, but CRP on day 3 had stronger
statistic power.
Conclusion: Both CRP and sTREM-1 on day 3 could be useful in predicting nonresponsive CAP patients.
Differential trends between sTREM-1 and CRP in nonresponsive CAP suggest that sTREM-1 could be an
adjuvant biomarker to CRP in predicting CAP patients without response to empiric treatment. [J Formos
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an unfavorable outcome so that we could modify
our treatment to improve it. Ioanas et al4–6 con-
ducted several studies on the predictors of non-
response in hospital-acquired pneumonia (HAP)
and ventilator-associated pneumonia (VAP). How-
ever, there are no reliable markers of CAP without
response to initial treatment.
C-reactive protein (CRP) is considered to be an
early nonspecific but sensitive marker of inflam-
mation.7 Evidence has shown the utility of CRP
as an effective diagnostic tool in CAP.8–11 Further-
more, Almirall et al12 found that CRP was not
only good for diagnosis, but also as an indicator
of severity. Po’voa et al13 further demonstrated
that the kinetic change in CRP could be used as 
a marker for mortality in patients with VAP.13
Triggering receptor expressed on myeloid cells-1
(TREM-1) is a recently discovered cell surface mole-
cule that has been identified on neutrophils and
a subset of monocytes. TREM-1 is a member of
the immunoglobulin superfamily, and its expres-
sion on phagocytes is specifically upregulated by
microbial products.14,15 Gibot et al16–18 conducted
several studies to evaluate the role of TREM-1 in
pneumonia and sepsis patients. Soluble TREM-1
(sTREM-1) is shed from the membrane of active
phagocytes and can be found in body fluids. In pa-
tients receiving mechanical ventilation, rapid de-
tection of sTREM-1 in bronchoalveolar lavage fluid
may be useful in establishing or excluding the di-
agnosis of bacterial or fungal pneumonia.16 In ad-
dition to sTREM-1 in bronchoalveolar lavage fluid,
plasma level of sTREM-1 has been shown to be
helpful in identifying critically ill patients suffer-
ing from infection.17 Besides, as a diagnostic tool
for pneumonia, Gibot et al also found that a pro-
gressive decline in plasma sTREM-1 concentration
indicates a favorable clinical evolution during the
recovery phase of sepsis.18 However, to our knowl-
edge, no similar study has been conducted to
evaluate the role of sTREM-1 in CAP patients.
Therefore, we studied the levels of both sTREM-1
and CRP in CAP patients on day 1 and day 3. We
investigated whether serial plasma sTREM-1 or
CRP change could serve as a novel marker for pre-
dicting treatment response in CAP patients.
Materials and Methods
Study population
This prospective cohort study was conducted from
September 1, 2004 to July 31, 2005, in Taichung
Veterans General Hospital in central Taiwan.
Patients were enrolled if they met the following
criteria: (1) new infiltrates on chest X-ray radi-
ograph (CXR) on arrival at our outpatient clinic or
emergency room, and (2) at least two of the follow-
ing: fever with an axillary temperature > 37.8°C or
< 35.5°C, leukocytosis or leukopenia with a white
blood cell (WBC) count > 10,000 or < 4000/μL,
pleuritic chest pain, shortness of breath, cough,
and purulent sputum. Patients were excluded if
they were under 14 years of age, nursing home
residents, or had been hospitalized within 14 days
before this admission. Patients were also excluded
if they were organ transplant recipients, receiving
prednisolone > 20 mg daily or had been receiving
an equivalent dosage for more than 14 days, had
malignant neoplasm, acquired immunodeficiency
syndrome, active pulmonary tuberculosis, or had
been diagnosed with empyema thoracis on the
first day of admission.19 Approval of the hospi-
tal’s institutional review board and informed con-
sent from patients or their relatives were obtained
before inclusion.
Basic data and pneumonia severity 
index (PSI) scores
Demographic data were collected including age,
sex, number of comorbid conditions (diabetes
mellitus, congestive heart failure, chronic airway
disease, neurologic disease, chronic liver disease,
chronic renal failure, psychiatric disease, depres-
sion/anxiety, history of smoking, and radiographic
results). Pneumonia severity was assessed accord-
ing to the PSI derived from a prediction rule by
Fine et al.20
Microbiologic cultures and diagnostic 
tests
Samples of blood were drawn for blood cultures
and serologic tests, including Chlamydia IgM,
Mycoplasma, and Legionella antibody. A sample of
spontaneous sputum or induction sputum was
obtained for Gram’s stain and Ziehl-Neelsen stain.
In addition, urine was collected on the first day of
admission for detection of soluble pneumococcal
antigen by antibody assay (Binax-1 Streptococcus
pneumoniae urinary antigen test; Binax, Portland,
ME, USA). CXR was performed on days 1 and 3,
respectively.
The pathogens of pneumonia were determined
by the results of the diagnostic tests performed and
the patients’ response to specific treatment. Bacterial
pneumonia was diagnosed whenever blood or spu-
tum samples isolated pathogenic bacteria that were
compatible with the Gram’s stain. Positive urine
pneumococcal antigen was considered significant
in this study. Moreover, Chlamydia, Mycoplasma, and
Legionella were also considered to be pathogens
whenever elevated titers of antibody were discov-
ered with clinical response to treatment.
Definition of nonresponse and its causes
The definition of nonresponse included any of
the following:21 (1) persistent fever (temperature
on day 3 higher than on day 1; (2) progression
on CXR pneumonia change; (3) requirement of
change to broader spectrum antibiotic therapy
empirically; and (4) deterioration of patient’s con-
dition requiring mechanical ventilation and chest
tube drainage. Initial inadequate antibiotic treat-
ment was defined as the lack of at least one an-
tibiotic to which all isolates were susceptible in
vitro from the moment when the diagnostic tech-
nique was performed. Besides, poor respiratory
function was defined as poor cough ability and
need for care staff to perform blind endotracheal
suction.
CRP assay
CRP was measured in serum samples by an auto-
mated latex-enhanced turbidimetric assay with an
analyzer (VITORS 950, Johnson & Johnson A/S,
Rochester, MN, USA). The assay was linear from
0.7 to 11 mg/dL. When data were above 11 mg/dL,
the sample was diluted to 2X–5X with specialty
diluent and reanalyzed. The level was expressed
as mean ± SEM mg/dL.
Measurements of sTREM-1 levels
Whole blood in 5 mL quantity was drawn on day
1 and day 3, respectively. After centrifugation at
4°C, plasma was separated into aliquots, and stored
at −70°C until the day of assay. Levels of plasma
sTREM-1 were measured by enzyme-linked immu-
noassay (Duo Set ELISA Development Kits, R&D
Systems, Minneapolis, MN, USA). The sTREM-1
levels were established in a sandwich assay by
comparison with standard curves according to the
recommendations of the manufacturer. All mea-
surements were performed in duplicate. The level
was expressed as mean ± SEM pg/mL.
Statistical analysis
Descriptive results of continuous variables were
expressed as mean ± SD. The results for plasma
sTREM-1 and CRP levels were expressed as mean±
SEM. Variables were tested for their association
with the outcome using the Pearson χ2 test for
categorical data and the Mann-Whitney U test
for numerical data. Comparison between the dif-
ferent groups was conducted using the Mann-
Whitney U test for numerical data and the Pearson
χ2 test for categorical data. The time course of
sTREM-1 and CRP plasma levels was assessed by
analysis of variance. Multivariate analysis was per-
formed using a logistic regression model to esti-
mate the odds ratio of mortality, along with the
95% confidence interval. For the purpose of the
multivariate analysis, sTREM-1 and CRP plasma
concentrations were transformed into quartiles.
Analysis was performed using SPSS version 10.0
(SPSS Inc., Chicago, IL, USA) for Windows. The
significance level was set at a p value < 0.05.
Results
Patient characteristics
Fifty-eight patients (male/female 43/15; mean age,
67 ± 21 years) were enrolled in the study. The pa-
tients’ characteristics and underlying conditions
are listed in Table 1. PSI was 77 ± 34 in the respon-
sive treatment group and 123 ± 29 in the nonre-
sponsive group. The hospital stays were longer in
TREM-1 in CAP
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the nonresponsive group (27 days) than in the
response group (11 days). One patient died of
further aspiration pneumonia in the response
group and one in the nonresponse group with
hypoxemia and septic shock status.
Bacteriologic diagnosis
Microbiologic identification was obtained in 35
patients (60%). The most frequently isolated etio-
logic agents were S. pneumoniae (n = 15, 26%)
and Klebsiella pneumoniae (n = 9, 15%). Other mi-
crobial agents (Haemophilus influenzae, Moraxella
catarrhalis, Escherichia coli, Citrobacter freundii, 
influenza A virus, and Pseudomonas aeruginosa) were
also diagnosed (Table 2). Among the 15 patients
with pneumococcal pneumonia, eight were diag-
nosed by positive urine pneumococcal antigen
and seven by sputum culture. Minimum inhibitory
concentration (MIC) results for the seven patients
were 0.023, 0.5, 2, 4, 4, 4, and 6, respectively.
Nine patients with K. pneumoniae had diabetes
mellitus (DM).
The causes of nonresponse
Twelve patients were nonresponsive to the em-
pirical treatment. Three cases (25%) were due to
W.C. Chao, et al
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Table 1. Baseline and follow-up characteristics of the study population
Response (n = 46) Nonresponse (n = 12) p
Male/female 33/13 10/2 NS
Age (yr) 66 68 NS
Smoking history 31 (67%) 10 (83%) NS
Diabetes mellitus 7 (15%) 2 (16%) NS
Chronic lung disease 20 (43%) 5 (42%) NS
Cerebral vascular accident 5 (11%) 3 (25%) NS
Chronic renal failure 1 (2%) 1 (8%) NS
Cardiovascular disease 4 (9%) 1 (8%) NS
Liver disease 1 (2%) 0 NS
Mean PSI score 77 123 < 0.001
PSI class I 10 (13%) 0
PSI class II 3 (4%) 0
PSI class III 19 (25%) 2 (16%)
PSI class IV 13 (17%) 5 (42%)
PSI class V 1 (2%) 5 (42%)
Hospital stay (d) 11 27 < 0.001
Day 1 sTREM-1 (pg/mL) 32.8 ± 6.7 61.7 ± 22.3 NS
Day 1 CRP (mg/dL) 18.8 ± 1.9 22.2 ± 3.4 NS
Day 1 WBC (/mm3) 12,926 ± 5143 13,375 ± 12,458 NS
Day 3 sTREM-1 (pg/mL) 28.1 ± 5.7 63.8 ± 25.7 NS
Day 3 CRP (mg/dL) 7.8 ± 1.1 17.7 ± 3.6 0.019
Day 3 WBC (/mm3) 7942 ± 3009 11,685 ± 3892 0.001
Mortality 2 (4%) 1 (8%) NS
PSI = pneumonia severity index; sTREM-1 = soluble triggering receptor expressed on myeloid cells-1; CRP = C-reactive protein; WBC =
white blood cell count.
initial inadequate antibiotics (K. pneumoniae with
ESBL, penicillin-resistant S. pneumoniae [MIC: 6],
and P. aeruginosa, respectively). Seven patients
(58%) had poor respiratory function and three
of them had superimposed hospital-acquired
pathogens. These seven patients with poor respi-
ratory function had either chronic obstructive pul-
monary disease or old cerebral vascular accident.
Due to old age and several comorbidities, their
mean PSI score was 131±33. Two younger patients
(32 and 39 years) had severe CAP complicated
with acute respiratory distress syndrome needing
noninvasive positive ventilation support after ad-
mission. The pathogens responsible for their con-
ditions were S. pneumoniae and influenza A virus,
respectively. Their PSI scores were also high (138
and 101, respectively) because of unstable vital
signs despite young age.
Serial changes in CRP, WBC, and sTREM-1
CRP, WBC, and sTREM-1 did not differ between
the response and nonresponse groups on day 1
(Table 1). Moreover, CRP, WBC, and sTREM-1 did
not differ among the five categories of PSI by
Fine et al20 on the first day of admission. In the re-
sponse group, CRP decreased significantly from
18.8 to 7.8 mg/dL (decrease of 58%, p = 0.000).
In the nonresponsive patients, CRP also decreased
(from 22.2 to 17.7 mg/dL, decrease of 20%,
p = 0.33). The WBC count declined from 12,926
to 7942 (39%) in the response group and from
13,375 to 11,685 (13%) in the nonresponse group.
In the response group, sTREM-1 decreased from
32.8 to 28.17 pg/mL (decrease of 15%, p = 0.017).
In the nonresponse group, sTREM-1 plasma con-
centrations remained stable or even increased a
little (from 61.7 to 63.8 pg/mL, increase of 3%,
p = 0.89). The trend in serial CRP data was similar
to that of WBC but different from that of sTREM-1.
Using multivariate logistic regression analysis,
both CRP on day 3 (p = 0.006) and sTREM-1 on
day 3 (p = 0.046) predicted treatment response
significantly, but CRP on day 3 had better statis-
tic power (Table 3). The serial change in plasma
sTREM-1 and CRP levels in relation to patients’
outcome are depicted in Figure 1. The receiver op-
erating characteristic curves of CRP and sTREM-1
on day 3 are shown in Figure 2.
TREM-1 in CAP
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Table 2. Microbial identification
Overall Response Nonresponse
Negative microbiologic findings 23 22 1
Streptococcus pneumoniae* 15 12 3
Klebsiella pneumoniae 9 6 3
Haemophilus influenzae 5 4 1
Moraxella catarrhalis 2 2 0
Escherichia coli† 1 0 1
Citrobacter freundii‡ 1 0 1
Influenza A virus 1 0 1
Pseudomonas aeruginosa 1 0 1
*Eight patients were diagnosed by positive urine pneumococcal antigen and seven patients by positive sputum culture; †by blood culture;
‡by bronchoalveolar lavage culture.
Table 3. Multivariate logistic regression
Variable Regression coefficient SE OR (95% CI) p
Day 3 CRP (mg/dL) 0.112 0.041 1.119 (1.033–1.211) 0.006
Day 3 sTREM-1 (pg/mL) 0.012 0.006 1.012 (1.000–1.024) 0.046
SE = standard error; OR = odds ratio; CI = confidence interval; CRP = C-reactive protein; sTREM-1 = soluble triggering receptor expressed
on myeloid cells-1.
Discussion
Our study evaluated the role of sTREM-1 and CRP
in the management of CAP. Though sTREM-1 was
persistently elevated in the nonresponse group
of CAP, we found that sTREM-1 was not better
than CRP in predicting treatment response of
CAP on days 1 and 3. In addition, microbiology-
confirmed pneumonia raised our attention to
penicillin drug-resistant S. pneumoniae and could
be a possible cause of treatment failure.
S. pneumoniae is the leading cause of CAP in
Taiwan as in other countries,22 and drug-resistant
S. pneumoniae has become a problem throughout
the world, including Taiwan. In this study, 15
(26%) of the 58 patients were diagnosed with
pneumococcal pneumonia. Eight of them were
diagnosed by positive urine pneumococcal anti-
gen and seven had positive sputum culture.
Surprisingly, we found that the MIC of these
seven patients was quite high (0.023, 0.5, 2, 4, 4,
4, and 6, respectively). Since this study included
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only CAP patients and none of them received an-
tibiotics before admittance to our hospital, the
extremely high incidence (5/7, 71%) of penicillin-
nonsusceptible S. pneumoniae (PNSSP) alerted 
us to the need to focus attention on this issue.
Lauderdale et al23 recently reported that 87.5%
of S. pneumoniae from nasopharyngeal culture of
children was penicillin resistant. Our results are
similar to their findings and imply that the carriage
rate of PNSSP is high in our community. PNSSP
was associated with only one patient who did not
respond to initial empiric treatment in our study.
K. pneumoniae is another common cause of CAP in
Taiwan, especially in DM patients.22 In this study,
K. pneumoniae was the second most common
pathogen; nine patients (15%) had K. pneumoniae-
related CAP and five among the nine patients were
DM patients.
Concerning the possible causes of nonresponse
to initial empiric treatment, only three (25%)
cases were due to initial inadequate antibiotics
either by resistant strain or inadequate antibiotic
spectrum. Genn et al24 reported that resistant 
organisms only comprised 6% of empirical treat-
ment failure cases of CAP. Moreover, the major-
ity (7/12, 58%) of nonresponsive cases in our
study were due to poor respiratory function fol-
lowed by hospital-acquired pathogens. Poor res-
piratory function was defined as poor cough
ability and need for care staff to perform blind
endotracheal suction. The seven patients with
poor respiratory function in our study had either
chronic obstructive pulmonary disease or old
cerebral vascular accident. In our study, no case
of PSI class I or II failed in the initial empiric
treatment. PSI was significantly higher in the
nonresponse group than in the response group.
Our results support those of Wu et al25 and Lin 
et al,26 indicating that PSI is a useful tool for 
predicting nonresponse in CAP in Taiwan. PSI
comprises two parts: the underlying condition
and the severity of the pneumonia. In CAP, the
empirical antibiotics can treat most of the pos-
sible pathogens, so the nonresponsive condition
is mostly due to either very severe initial infec-
tion or poor respiratory condition followed by
hospital-acquired pathogens. Therefore, non-
responsive CAP patients can be classified into
three groups: healthy people with very severe 
infection, those with poor respiratory function
with or without severe infection accompanied by 
hospital-acquired pathogens, and those who are
resistant to initial empiric treatment.
Since 10–20% of CAP patients fail in their
initial empiric treatment, it is important to iden-
tify these types of patients as early as possible by
clinical signs or biomarkers. Efforts have thus
been made to find a reliable biomarker of infec-
tion. Among the currently used biomarkers, CRP
has been used for decades in CAP, and procalci-
tonin (PCT) has been proposed as the most prom-
ising one in recent years.27–29 In addition to CRP
and PCT, sTREM-1 has recently been used as a bio-
marker. Gibot et al16,17 reported that the determi-
nation of the level of sTREM-1 in such biological
fluids as plasma or bronchoalveolar lavage fluid
could help identify the presence of an infectious
process more quickly. Moreover, they also showed
that evaluating changes in sTREM-1 over time
was useful in assessing the effects of therapeutic
interventions.18 However, most studies of PCT
and sTREM-1 were conducted in patients with
sepsis or in intensive care unit patients, whereas,
to our knowledge, our study is the first to evalu-
ate whether serial changes in sTREM-1 could also
be used for early assessment of the effect of ther-
apeutic interventions among patients with CAP.
In the response group, both CRP and sTREM-1
declined significantly from day 1 to day 3. CRP
declined from 18.8 to 7.8 (decrease of 58%),
whereas sTREM-1 declined from 32.8 to 28.1
(decrease of 15%). But in the nonresponse group,
CRP still decreased from 22.2 to 17.7 (decrease
of 20%), whereas sTREM-1 increased from 61.7
to 63.8 (increase of 3%). The WBC count declined
from 12,926 to 7942 (39%) in the response
group and from 13,375 to 11,685 (13%) in the
nonresponse group, and its serial change was the
same as CRP. Based on the above data, we can use
the serial change in CRP and sTREM-1 to predict
clinical response or nonresponse. If we use CRP
as a marker of treatment response, we should 
TREM-1 in CAP
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not only focus on the decrease in CRP level but
also on the magnitude of decrease. Such a con-
cept is similar to that in the study by Po’voa et al,
who used a CRP drop of 40% as a cutoff value 
to predict mortality (sensitivity, 0.92; specificity,
0.59) among patients with VAP. In our study, 
in terms of sTREM-1 serial change, the level of
sTREM-1 remained persistently elevated on day 3
in the nonresponse group, but had rapidly de-
creased in the response group. Therefore, persist-
ent elevation of plasma sTREM-1 concentrations
might help in identifying subgroups of patients
who are not able to clear their infection effi-
ciently and thus require a clinician to reevaluate
treatment.
A potential limitation of this study is the lim-
ited number of cases of pure CAP in our teaching
hospital. Furthermore, only 10–20% of CAP pa-
tients fail in their initial empiric treatment ac-
cording to current CAP treatment guidelines.3
However, our study still has an important impli-
cation for clinicians. CRP has been used for
decades in CAP, but no clear-cut value has been
defined as to how much of a CRP drop denotes a
good response to empirical treatment. In this
study, we found that serial plasma sTREM-1
could be an adjuvant biomarker to CRP to detect
nonresponsive CAP early. Therefore, it might
help guide physicians in their clinical decision
making, especially among patients in whom the
response is not clinically straightforward.
In conclusion, we found that the hospital-
based core pathogens of CAP were S. pneumoniae
and K. pneumoniae. PNSSP is common in our
CAP patients. The causes of nonresponse to ini-
tial empiric treatment include: healthy indivi-
duals with very severe infection, those with poor
respiratory function with or without severe in-
fection followed by hospital-acquired pathogens,
and those who are resistant to initial empiric
treatment. Both day 3 CRP and sTREM-1 could
be useful in predicting CAP patients without 
response to initial treatment, although CRP had
stronger statistic power. The serial changes in
CRP and sTREM-1 in CAP patients were different
from those in nonresponsive CAP patients, and
persistent elevation of sTREM-1 suggested nonre-
sponse. In our study, sTREM was found to be an
adjuvant biomarker to CRP to detect nonrespon-
sive CAP patients early.
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